Germline Missense Variants in CDC20 Result in Aberrant Mitotic Progression and Familial Cancer

Author:

Chen Owen J.12ORCID,Castellsagué Ester345ORCID,Moustafa-Kamal Mohamed12ORCID,Nadaf Javad6,Rivera Barbara789ORCID,Fahiminiya Somayyeh310,Wang Yilin12,Gamache Isabelle1,Pacifico Caterina111,Jiang Lai712ORCID,Carrot-Zhang Jian310ORCID,Witkowski Leora34,Berghuis Albert M.21314,Schönberger Stefan15ORCID,Schneider Dominik16ORCID,Hillmer Morten17,Bens Susanne17,Siebert Reiner17,Stewart Colin J.R.18,Zhang Ziguo19ORCID,Chao William C.H.20,Greenwood Celia M.T.71221ORCID,Barford David19ORCID,Tischkowitz Marc22ORCID,Majewski Jacek310ORCID,Foulkes William D.342324ORCID,Teodoro Jose G.1214ORCID

Affiliation:

1. 1Goodman Cancer Institute, McGill University, Montréal, Québec, Canada.

2. 2Department of Biochemistry, McGill University, Montréal, Québec, Canada.

3. 3Department of Human Genetics, McGill University, Montréal, Québec, Canada.

4. 4Division of Medical Genetics and Cancer Axis, Lady Davis Institute, Segal Cancer Centre, Jewish General Hospital, Montréal, Québec, Canada.

5. 5Translational Research Laboratory, Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research, L'Hospitalet de Llobregat, Barcelona, Spain.

6. 6McGill University and Génome Québec Innovation Centre, Montréal, Québec, Canada.

7. 7Cancer Axis, Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada.

8. 8Hereditary Cancer Programme, Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research, L'Hospitalet de Llobregat, Barcelona, Spain.

9. 9Gerald Bronfman Department of Oncology, McGill University, Montréal, Québec, Canada.

10. 10Cancer Research Program, Research Institute of the McGill University Health Centre, Montréal, Québec, Canada.

11. 11Department of Biology, McGill University, Montréal, Québec, Canada.

12. 12Department of Epidemiology, Biostatistics & Occupational Health, McGill University, Montréal, Québec, Canada.

13. 13Centre de Recherche en Biologie Structurale, McGill University, Montréal, Québec, Canada.

14. 14Department of Microbiology and Immunology, Montréal, Québec, Canada.

15. 15Department of Pediatric Hematology and Oncology, Pediatrics III, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany.

16. 16Clinic of Pediatrics, Dortmund Municipal Hospital, Dortmund, Germany.

17. 17Institute of Human Genetics, University of Ulm & Ulm University Medical Center, Ulm, Germany.

18. 18Department of Histopathology, King Edward Memorial Hospital, and School for Women's and Infants’ Health, University of Western Australia, Perth, Australia.

19. 19Institute of Cancer Research, London, United Kingdom.

20. 20Faculty of Health Sciences, University of Macau, Macau SAR, China.

21. 21Departments of Oncology and Human Genetics, McGill University, Montréal, Québec, Canada.

22. 22Department of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, United Kingdom.

23. 23Program in Cancer Genetics, Department of Oncology and Human Genetics, McGill University, Montréal, Québec, Canada.

24. 24Division of Medical Genetics and Cancer Research Program, Research Institute of the McGill University Health Centre, Montréal, Québec, Canada.

Abstract

Abstract CDC20 is a coactivator of the anaphase promoting complex/cyclosome (APC/C) and is essential for mitotic progression. APC/CCDC20 is inhibited by the spindle assembly checkpoint (SAC), which prevents premature separation of sister chromatids and aneuploidy in daughter cells. Although overexpression of CDC20 is common in many cancers, oncogenic mutations have never been identified in humans. Using whole-exome sequencing, we identified heterozygous missense CDC20 variants (L151R and N331K) that segregate with ovarian germ cell tumors in two families. Functional characterization showed these mutants retain APC/C activation activity but have impaired binding to BUBR1, a component of the SAC. Expression of L151R and N331K variants promoted mitotic slippage in HeLa cells and primary skin fibroblasts derived from carriers. Generation of mice carrying the N331K variant using CRISPR-Cas9 showed that, although homozygous N331K mice were nonviable, heterozygotes displayed accelerated oncogenicity of Myc-driven cancers. These findings highlight an unappreciated role for CDC20 variants as tumor-promoting genes. Significance: Two germline CDC20 missense variants that segregate with cancer in two families compromise the spindle assembly checkpoint and lead to aberrant mitotic progression, which could predispose cells to transformation. See related commentary by Villarroya-Beltri and Malumbres, p. 3432

Funder

Canadian Institutes of Health Research

Rare Diseases: Models and Mechanisms Network

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3